Francesca Fanini
@irst.emr.it
Scopus Publications
- Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study
Caterina Gianni, Emanuela Scarpi, Sara Bravaccini, Francesca Pirini, Silvia Vanni, Monia Dall’Agata, Michela Cortesi, Francesca Fanini, Sara Cavalieri, Laura Mercatali, Paola Ulivi, Alessandra Poini, Carlo Maria Giovanardi, Andrea Rocca, Anna Fedeli
Supportive Care in Cancer, 2025 - Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products
Anna Maria Granato, Elena Pancisi, Claudia Piccinini, Monica Stefanelli, Sara Pignatta, Valentina Soldati, Silvia Carloni, Francesca Fanini, Chiara Arienti, Jenny Bulgarelli, Marcella Tazzari, Emanuela Scarpi, Alessandro Passardi, Francesca Tauceri, Giuliano La Barba, Giuseppe Maimone, Stefano Baravelli, Francesco de Rosa, Laura Ridolfi, Massimiliano Petrini
Cytotherapy, 2024
BACKGROUND AIMS: Dendritic cells (DCs) are professional antigen-presenting cells of the mammalian immune system. Ex vivo differentiated DCs represent a unique Advanced Therapy Medicinal Product (ATMP), used in several clinical trials as personalized cancer immunotherapy. The therapy's reliability depends on its capacity to produce high-quality mature DCs (mDCs) in compliance with Good Manufacturing Practices. AIMS: From March 2010 to December 2023, 103 patients were enrolled in multiple clinical trials at the Immuno-Gene Therapy Factory at IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori". Six hundred forty-two doses were produced, and the manufacturing process was implemented to optimize production. Our study is a retrospective analysis focusing on the quality control results. METHODS: We retrospectively analyzed the results of the quality control tests carried out on each produced batch, evaluating viability, purity and phenotype of mDCs and their quality in terms of microbiological safety. The data obtained are given with median and interquartile range. RESULTS: The batches were found to be microbiologically safe in terms of sterility, mycoplasma, and endotoxins. An increase in DC maturation markers was found. The release criteria checks showed a high percentage of viability and purity was maintained during the production process. CONCLUSIONS: Our findings have confirmed that the measures implemented have ensured the safety of the products and have contributed to the establishing a robust "Pharmaceutical Quality System." This has enabled many safe mDCs to be produced for clinical trials. - In vitro CAR-T cell killing: validation of the potency assay
Claudia Piccinini, Silvia Carloni, Chiara Arienti, Elena Pancisi, Francesca Fanini, Sara Pignatta, Valentina Soldati, Monica Stefanelli, Anna Maria Granato, Giovanni Martinelli, Laura Ridolfi, Massimiliano Petrini
Cancer Immunology Immunotherapy, 2024
For advanced therapy medicinal products, the development and validation of potency assays are required, in accordance with international guidelines, to characterise the product and obtain reliable and consistent data. Our purpose was to validate the killing assay for the evaluation of autologous anti-CD19 chimeric antigen receptor (CAR) T potency. We used CD4 + and CD8 + lymphocytes or anti-CD19 CAR-T cells as effector cells and REH (CD19 +) or MOLM-13 (CD19 −) cell lines as target cells. After co-culturing target and effector cells (1:1 ratio) for 24 h, samples were labelled with 7-AAD, anti-CD3 and anti-CD19 antibodies and the frequency of CD19 + dead cells was evaluated by flow cytometry. In order to verify the CAR-T specificity for the CD19 + target, the co-culture between CAR-T and REH or MOLM-13 at different effector-to-target ratios was scheduled. Moreover, not transduced CD4 + and CD8 + lymphocytes were tested in comparison with CAR-T from the same donor to demonstrate the assay specificity. Linearity and accuracy were evaluated, and established acceptance criteria were compiled for both parameters (r2 ≥ 0.97 for linearity and average relative error ≤ 10% for accuracy). Furthermore, the method was considered robust when performed between 23 and 25 h of co-culture, and the intra-assay, inter-assay and inter-day precision was obtained. Finally, in order to verify the inter-analyst precision, the test was executed by three different operators and the intra-class correlation coefficient was > 0.4 in both cases. In conclusion, we consider this CAR-T potency assay as validated and usable in all steps of product development and quality control. - Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center
Elena Pancisi, Anna Maria Granato, Emanuela Scarpi, Laura Ridolfi, Silvia Carloni, Cinzia Moretti, Massimo Guidoboni, Francesco De Rosa, Sara Pignatta, Claudia Piccinini, Valentina Soldati, Luana Calabrò, Massimo Framarini, Monica Stefanelli, Jenny Bulgarelli, Marcella Tazzari, Francesca Fanini, Massimiliano Petrini
Vaccines, 2022
Advanced therapy medical products (ATMPs) are rapidly growing as innovative medicines for the treatment of several diseases. Hence, the role of quality analytical tests to ensure consistent product safety and quality has become highly relevant. Several clinical trials involving dendritic cell (DC)-based vaccines for cancer treatment are ongoing at our institute. The DC-based vaccine is prepared via CD14+ monocyte differentiation. A fresh dose of 10 million DCs is administered to the patient, while the remaining DCs are aliquoted, frozen, and stored in nitrogen vapor for subsequent treatment doses. To evaluate the maintenance of quality parameters and to establish a shelf life of frozen vaccine aliquots, a stability program was developed. Several parameters of the DC final product at 0, 6, 12, 18, and 24 months were evaluated. Our results reveal that after 24 months of storage in nitrogen vapor, the cell viability is in a range between 82% and 99%, the expression of maturation markers remains inside the criteria for batch release, the sterility tests are compliant, and the cell costimulatory capacity unchanged. Thus, the data collected demonstrate that freezing and thawing do not perturb the DC vaccine product maintaining over time its functional and quality characteristics. - Microrna-16 restores sensitivity to tyrosine kinase inhibitors and outperforms mek inhibitors in kras-mutated non-small cell lung cancer
Francesca Fanini, Erika Bandini, Meropi Plousiou, Silvia Carloni, Petra Wise, Paolo Neviani, Mariam Murtadha, Flavia Foca, Francesco Fabbri, Ivan Vannini, Muller Fabbri
International Journal of Molecular Sciences, 2021
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Chemotherapy, the treatment of choice in non-operable cases, achieves a dismal success rate, raising the need for new therapeutic options. In about 25% of NSCLC, the activating mutations of the KRAS oncogene define a subclass that cannot benefit from tyrosine kinase inhibitors (TKIs). The tumor suppressor miR-16 is downregulated in many human cancers, including NSCLC. The main objectives of this study were to evaluate miR-16 treatment to restore the TKI sensitivity and compare its efficacy to MEK inhibitors in KRAS-mutated NSCLC. Methods: We performed in vitro and in vivo studies to investigate whether miR-16 could be exploited to overcome TKI resistance in KRAS-mutated NSCLC. We had three goals: first, to identify the KRAS downstream effectors targeted by mir-16, second, to study the effects of miR-16 restoration on TKI resistance in KRAS-mutated NSCLC both in vitro and in vivo, and finally, to compare miR-16 and the MEK inhibitor selumetinib in reducing KRAS-mutated NSCLC growth in vitro and in vivo. Results: We demonstrated that miR-16 directly targets the three KRAS downstream effectors MAPK3, MAP2K1, and CRAF in NSCLC, restoring the sensitivity to erlotinib in KRAS-mutated NSCLC both in vitro and in vivo. We also provided evidence that the miR-16–erlotinib regimen is more effective than the selumetinib–erlotinib combination in KRAS-mutated NSCLC. Conclusions: Our findings support the biological preclinical rationale for using miR-16 in combination with erlotinib in the treatment of NSCLC with KRAS-activating mutations. - Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: A retrospective single-center study
Fei Xu, Zhu Zeng, Bing Yan, Yiqi Fu, Yilan Sun, Guangdie Yang, Lingfang Tu, Satoshi Watanabe, Salma K. Jabbour, Sara Bravaccini, Francesca Fanini, Jianying Zhou, Yihong Shen
Translational Lung Cancer Research, 2021
Background Programmed death protein (ligand) 1 [PD-(L)1] inhibitors have provided new therapeutic options for advanced lung cancer. However, patients with hepatitis B virus (HBV) infection have been traditionally excluded from most registered trials of this form of treatment. Methods We performed a retrospective analysis of patients with HBV and advanced lung cancer who received anti-PD-1 immunotherapy from September 2018 to May 2020 in our department. Treatment-related hepatotoxicity was evaluated and recorded. Overall response rate and progression free survival were also assessed in the patients using iRECIST. Results Seventeen patients were evaluated in this analysis. Of these, six (35.3%) experienced hepatic transaminase elevation during immunotherapy. Three of these patients developed Grade 3 hepatic immune-related adverse events and received systemic corticosteroids, following which aminotransferase levels recovered to normal in all patients and no adverse events were observed in subsequent treatment. No patient experienced HBV reactivation or flare. One patient developed active pulmonary tuberculosis (TB). Other adverse events were mild, well tolerated and short term. The objective response rate (ORR) of the cohort was 62.5%, and the median progression-free survival (PFS) was 3 months. Conclusions Lung cancer patients can be treated safely with anti-PD-1 inhibitors in the context of HBV infection. Close monitoring for hepatotoxicity and prophylactic antiviral therapy is advised. Further studies on the use of anti-PD-1 inhibitors in HBV-infected patients are needed. - miR-9-5p as a Regulator of the Androgen Receptor Pathway in Breast Cancer Cell Lines
Erika Bandini, Francesca Fanini, Ivan Vannini, Tania Rossi, Meropi Plousiou, Maria Maddalena Tumedei, Francesco Limarzi, Roberta Maltoni, Francesco Fabbri, Silvana Hrelia, William C. S. Cho, Muller Fabbri
Frontiers in Cell and Developmental Biology, 2020
Breast cancer (BC) is the most diagnosed carcinoma and the leading cause of cancer death in female over 100 countries. Thanks to the advance in therapeutic strategies, patients’ survival has improved. However, the lack of response to treatments and drug resistance are still a main concern, demanding for new therapeutic approaches, in particular for the advanced stages of the disease. Androgen receptor (AR) is gaining increasing interest as a fourth targetable receptor in BC, however, its regulation in BC cells is still poorly understood. MicroRNAs (miRNAs) regulate gene expression post-transcriptionally. Here, we identified miR-9-5p as an inhibitor of AR expression, we validated the inverse correlation between miR-9-5p and AR in primary BC samples and we further identified a feedback loop in which androgen agonists of AR up-regulate miR-9-5p. We also provided evidence that miR-9-5p elicits anti-proliferative effects in BC cell lines regardless of their estrogen receptor status. Finally, we showed that miR-9-5p can revert AR-downstream signaling even in presence of AR-agonists, highlighting the role of this miR in the hormonal response of BC. In conclusion, this study supports the role of miR-9-5p as an anti-proliferative miR in BC and as a central modulator of AR-signaling response to circulating androgens in BC. - Microbiota-derived metabolites in tumor progression and metastasis
Tania Rossi, Daniele Vergara, Francesca Fanini, Michele Maffia, Sara Bravaccini, Francesca Pirini
International Journal of Molecular Sciences, 2020
Microbial communities and human cells, through a dynamic crosstalk, maintain a mutualistic relationship that contributes to the maintenance of cellular metabolism and of the immune and neuronal systems. This dialogue normally occurs through the production and regulation of hormonal intermediates, metabolites, secondary metabolites, proteins, and toxins. When the balance between host and microbiota is compromised, the dynamics of this relationship change, creating favorable conditions for the development of diseases, including cancers. Microbiome metabolites can be important modulators of the tumor microenvironment contributing to regulate inflammation, proliferation, and cell death, in either a positive or negative way. Recent studies also highlight the involvement of microbiota metabolites in inducing epithelial–mesenchymal transition, thus favoring the setup of the metastatic niche. An investigation of microbe-derived metabolites in “liquid” human samples, such as plasma, serum, and urine, provide further information to clarify the relationship between host and microbiota. - Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience
Michela Palleschi, Roberta Maltoni, Sara Ravaioli, Alessandro Vagheggini, Francesca Mannozzi, Francesca Fanini, Francesca Pirini, Maria Tumedei, Eleonora Barzotti, Lorenzo Cecconetto, Samanta Sarti, Silvia Manunta, Paola Possanzini, Anna Fedeli, Annalisa Curcio, Mattia Altini, Ugo De Giorgi, Andrea Rocca, Sara Bravaccini
Diagnostics, 2020
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of progesterone receptor (PR) and Ki67, assessed by immunohistochemistry, in 71 ABC patients treated with CDK4/6i and analyzed the impact of these markers on progression-free survival (PFS). The majority of patients 63/71 (88.7%) received palbociclib, 4 (5.6%) received ribociclib, and 4 (5.6%) received abemaciclib. A higher median value of Ki67 was observed in cases undergoing second-line treatment (p = 0.047), whereas the luminal B subtype was more prevalent (p = 0.005). In the univariate analysis of the first-line setting, luminal A subtype showed a trend towards a correlation with a longer PFS (p = 0.053). A higher continuous Ki67 value led to a significantly shorter PFS. When the interaction between pathological characteristics and line of treatment was considered, luminal B subtype showed a significantly (p = 0.043) worse outcome (Hazard Ratio (HR) 2.84; 1.03–7.82 95% Confidence Interval (CI)). PFS in patients undergoing endocrine therapy plus CDK4/6i was inversely correlated with Ki67 expression but not with PR, suggesting that tumor proliferation has a greater impact on cell cycle inhibitors combined with endocrine therapy than PR expression. - ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients
Sara Ravaioli, Michela Tebaldi, Eugenio Fonzi, Davide Angeli, Massimiliano Mazza, Fabio Nicolini, Alessandro Lucchesi, Francesca Fanini, Francesca Pirini, Maria Maddalena Tumedei, Claudio Cerchione, Pierluigi Viale, Vittorio Sambri, Giovanni Martinelli, Sara Bravaccini
Cell Transplantation, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. One open question is whether genetics could influence the severity of symptoms. Considering the limited data on cancer patients, we analyzed public data repositories limited to investigate angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine protease 2 (TMPRSS2) expressions and genetic variants to identify the basis of individual susceptibility to SARS-CoV-2. Gene expression and variant data were retrieved from Tissue Cancer Genome Atlas, Genotype-Tissue Expression, and gnomAD. Differences in gene expression were tested with Mann-Whitney U-test. Allele frequencies of germline variants were explored in different ethnicities, with a special focus on ACE2 variants located in the binding site to SARS-CoV-2 spike protein. The analysis of ACE2 and TMPRSS2 expressions in healthy tissues showed a higher expression in the age class 20 to 59 years (false discovery rate [FDR] < 0.0001) regardless of gender. ACE2 and TMPRSS2 were more expressed in tumors from males than females (both FDR < 0.0001) and, opposite to the regulation in tissues from healthy individuals, more expressed in elderly patients (FDR = 0.005; FDR < 0.0001, respectively). ACE2 and TMPRSS2 expressions were higher in cancers of elderly patients compared with healthy individuals (FDR < 0.0001). Variants were present at low frequency (range 0% to 3%) and among those with the highest frequency, the variant S19P belongs to the SARS-CoV-2 spike protein binding site and it was exclusively present in Africans with a frequency of 0.2%. The mechanisms of ACE2 and TMPRSS2 regulation could be targeted for preventive and therapeutic purposes in the whole population and especially in cancer patients. Further studies are needed to show a direct correlation of ACE2 and TMPRSS2 expressions in cancer patients and the incidence of COVID-19. - Corrigendum to “MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis” (MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis (2013) 46(10–11) (918–925), (S0009912013000520), (10.1016/j.clinbiochem.2013.01.024))
Ivan Vannini, Francesca Fanini, Muller Fabbri
Clinical Biochemistry, 2019 - MicroRNAs and androgen receptor: Emerging players in breast cancer
Erika Bandini, Francesca Fanini
Frontiers in Genetics, 2019 - Corrigendum to “MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis” (MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis (2013) 46(10–11) (918–925), (S0009912013000520) (10.1016/j.clinbiochem.2013.01.024))
Ivan Vannini, Francesca Fanini, Muller Fabbri
Clinical Biochemistry, 2019 - Emerging roles of microRNAs in cancer
Ivan Vannini, Francesca Fanini, Muller Fabbri
Current Opinion in Genetics and Development, 2018 - Erratum: Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs (Nature communications (2017) 8 1 (1801))
Ivan Vannini, Petra M. Wise, Kishore B. Challagundla, Meropi Plousiou, Mirco Raffini, Erika Bandini, Francesca Fanini, Giorgia Paliaga, Melissa Crawford, Manuela Ferracin, Cristina Ivan, Linda Fabris, Ramana V. Davuluri, Zhiyi Guo, Maria Angelica Cortez, Xinna Zhang, Lu Chen, Shuxing Zhang, Cecilia Fernandez-Cymering, Leng Han, Silvia Carloni, Samanta Salvi, Hui Ling, Mariam Murtadha, Paolo Neviani, Barbara J. Gitlitz, Ite A. Laird-Offringa, Patrick Nana-Sinkam, Massimo Negrini, Han Liang, Dino Amadori, Amelia Cimmino, George A. Calin, Muller Fabbri
Nature Communications, 2018 - Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs
Ivan Vannini, Petra M. Wise, Kishore B. Challagundla, Meropi Plousiou, Mirco Raffini, Erika Bandini, Francesca Fanini, Giorgia Paliaga, Melissa Crawford, Manuela Ferracin, Cristina Ivan, Linda Fabris, Ramana V. Davuluri, Zhiyi Guo, Maria Angelica Cortez, Xinna Zhang, Lu Chen, Shuxing Zhang, Cecilia Fernandez-Cymering, Leng Han, Silvia Carloni, Samanta Salvi, Hui Ling, Mariam Murtadha, Paolo Neviani, Barbara J. Gitlitz, Ite A. Laird-Offringa, Patrick Nana-Sinkam, Massimo Negrini, Han Liang, Dino Amadori, Amelia Cimmino, George A. Calin, Muller Fabbri
Nature Communications, 2017 - Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: Preclinical rationale and phase II study results
Alessandro Passardi, Francesca Fanini, Livia Turci, Flavia Foca, Paola Rosetti, Silvia Ruscelli, Andrea Casadei Gardini, Martina Valgiusti, Claudio Dazzi, Maurizio Marangolo
Oncologist, 2017 - Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art
Francesca Fanini, Muller Fabbri
Seminars in Cell and Developmental Biology, 2017 - Combining anti-miR-155 with chemotherapy for the treatment of lung cancers
Katrien Van Roosbroeck, Francesca Fanini, Tetsuro Setoyama, Cristina Ivan, Cristian Rodriguez-Aguayo, Enrique Fuentes-Mattei, Lianchun Xiao, Ivan Vannini, Roxana S. Redis, Lucilla D'Abundo, Xinna Zhang, Milena S. Nicoloso, Simona Rossi, Vianey Gonzalez-Villasana, Rajesha Rupaimoole, Manuela Ferracin, Fortunato Morabito, Antonino Neri, Peter P. Ruvolo, Vivian R. Ruvolo, Chad V. Pecot, Dino Amadori, Lynne Abruzzo, Steliana Calin, Xuemei Wang, M. James You, Alessandra Ferrajoli, Robert Orlowski, William Plunkett, Tara M. Lichtenberg, Ramana V. Davuluri, Ioana Berindan-Neagoe, Massimo Negrini, Ignacio I. Wistuba, Hagop M. Kantarjian, Anil K. Sood, Gabriel Lopez-Berestein, Michael J. Keating, Muller Fabbri, George A. Calin
Clinical Cancer Research, 2017 - The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis
Hui Ling, Karen Pickard, Cristina Ivan, Claudio Isella, Mariko Ikuo, Richard Mitter, Riccardo Spizzo, Marc D Bullock, Cornelia Braicu, Valentina Pileczki, Kimberly Vincent, Martin Pichler, Verena Stiegelbauer, Gerald Hoefler, Maria I Almeida, Annie Hsiao, Xinna Zhang, John N Primrose, Graham K Packham, Kevin Liu, Krishna Bojja, Roberta Gafà, Lianchun Xiao, Simona Rossi, Jian H Song, Ivan Vannini, Francesca Fanini, Scott Kopetz, Patrick Zweidler-McKay, Xuemei Wang, Calin Ionescu, Alexandru Irimie, Muller Fabbri, Giovanni Lanza, Stanley R Hamilton, Ioana Berindan-Neagoe, Enzo Medico, Alex H Mirnezami, George A Calin, Milena S Nicoloso
Gut, 2016 - MicroRNAs and cancer resistance: A new molecular plot
F Fanini, M Fabbri
Clinical Pharmacology and Therapeutics, 2016 - Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy
Kishore B. Challagundla, Petra M. Wise, Paolo Neviani, Haritha Chava, Mariam Murtadha, Tong Xu, Rebekah Kennedy, Cristina Ivan, Xinna Zhang, Ivan Vannini, Francesca Fanini, Dino Amadori, George A. Calin, Michael Hadjidaniel, Hiroyuki Shimada, Ambrose Jong, Robert C. Seeger, Shahab Asgharzadeh, Amir Goldkorn, Muller Fabbri
Journal of the National Cancer Institute, 2015 - MicroRNAs and dendritic cell-based vaccination in melanoma patients
Francesco de Rosa, Francesca Fanini, Massimo Guidoboni, Ivan Vannini, Dino Amadori, Ruggero Ridolfi, Laura Ridolfi, Muller Fabbri
Melanoma Research, 2014 - MicroRNAs in the tumor microenvironment: Solving the riddle for a better diagnostics
Kishore B Challagundla, Francesca Fanini, Ivan Vannini, Petra Wise, Mariam Murtadha, Lawrence Malinconico, Amelia Cimmino, Muller Fabbri
Expert Review of Molecular Diagnostics, 2014 - MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis
Ivan Vannini, Francesca Fanini, Muller Fabbri
Clinical Biochemistry, 2013 - Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells
Maria I. Almeida, Milena S. Nicoloso, Lizhi Zeng, Cristina Ivan, Riccardo Spizzo, Roberta Gafà, Lianchun Xiao, Xinna Zhang, Ivan Vannini, Francesca Fanini, Muller Fabbri, Giovanni Lanza, Rui M. Reis, Patrick A. Zweidler–McKay, George A. Calin
Gastroenterology, 2012 - Clinical implications of microRNAs in lung cancer
Francesca Fanini, Ivan Vannini, Dino Amadori, Muller Fabbri
Seminars in Oncology, 2011 - MicroRNAs and drug modulation in cancer: An intertwined new story
Francesca Fanini, Ivan Vannini, Muller Fabbri
Frontiers in Biology, 2011 - Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of b-cell chronic lymphocytic leukemia
Muller Fabbri, Arianna Bottoni, Masayoshi Shimizu, Riccardo Spizzo, Milena S. Nicoloso, Simona Rossi, Elisa Barbarotto, Amelia Cimmino, Brett Adair, Sylwia E. Wojcik, Nicola Valeri, Federica Calore, Deepa Sampath, Francesca Fanini, Ivan Vannini, Gerardo Musuraca, Marie Dell’Aquila, Hansjuerg Alder, Ramana V. Davuluri, Laura Z. Rassenti, Massimo Negrini, Tatsuya Nakamura, Dino Amadori, Neil E. Kay, Kanti R. Rai, Michael J. Keating, Thomas J. Kipps, George A. Calin, Carlo M. Croce
JAMA, 2011 - Tumorlets in familial history of bronchopulmonary carcinoid
Ugo De Giorgi, Francesca Fanini, Dino Amadori, Alessandra Cancellieri, Giammaria Fiorentini, Venerino Poletti, Luisa Barzon, Giulia Masi
Journal of Thoracic Oncology, 2011 - Modulation of mismatch repair and genomic stability by miR-155
Nicola Valeri, Pierluigi Gasparini, Muller Fabbri, Chiara Braconi, Angelo Veronese, Francesca Lovat, Brett Adair, Ivan Vannini, Francesca Fanini, Arianna Bottoni, Stefan Costinean, Sukhinder K. Sandhu, Gerard J Nuovo, Hansjuerg Alder, Roberta Gafa, Federica Calore, Manuela Ferracin, Giovanni Lanza, Stefano Volinia, Massimo Negrini, Michael A. McIlhatton, Dino Amadori, Richard Fishel, Carlo M. Croce
Proceedings of the National Academy of Sciences of the United States of America, 2010 - Enzymatic descemetic lamellar keratoplasty: Pilot study
Paolo Bond, Paola Bond, Vincenzo Delia Malle, Francesca Fanini, Angela Nardi-Pantoli
European Journal of Ophthalmology, 2010 - Epigenetics, miRNAs, and human cancer: A new chapter in human gene regulation
Nicola Valeri, Ivan Vannini, Francesca Fanini, Federica Calore, Brett Adair, Muller Fabbri
Mammalian Genome, 2009
